Omada Health (NASDAQ:OMDA) Releases Earnings Results, Beats Estimates By $0.03 EPS

Omada Health (NASDAQ:OMDA) issued its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03, FiscalAI reports. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.85%. The company had revenue of $78.05 million during the quarter.

Here are the key takeaways from Omada Health’s conference call:

• Q1 results beat on growth and profitability: $78 million revenue (+42% YoY), GAAP net loss narrowed to $3M, positive adjusted EBITDA ($1M), and management raised full‑year guidance to $322–330M revenue and $14–20M adjusted EBITDA.
• Total membership scaled past 1,025,000 (+51% YoY) with 139k net adds in Q1, and enrollment gains were broad across GLP‑1, hypertension, and diabetes programs.
• Commercial reach expanded materially for GLP‑1 and cardiometabolic care: Omada joined Optum Rx Weight Engage and Lilly Employer Connect, now has relationships with the three largest PBMs and has launched prescribing capabilities (meaningful prescribing revenue expected to scale into 2027).
• AI and automation are being deployed company‑wide (care‑team tooling, product development, operational workflows), which management says is improving productivity and provides a structural tailwind to margins and potential to exceed the >70% gross margin target.
• Unit economics are shifting as members stay longer: blended revenue per member may be pressured near term while gross profit per member and overall margins improve as cohorts mature — a deliberate tradeoff for longer‑term profitability.

Omada Health Trading Down 9.6%

Shares of OMDA traded down $1.58 during mid-day trading on Friday, reaching $14.82. 3,232,593 shares of the stock traded hands, compared to its average volume of 865,900. The company has a market cap of $880.60 million and a price-to-earnings ratio of -54.89. Omada Health has a 1 year low of $10.28 and a 1 year high of $28.40. The firm has a fifty day moving average price of $13.55 and a 200 day moving average price of $15.85.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Barclays raised its price target on Omada Health and kept an overweight rating, pointing to meaningful upside from current levels. Barclays raises OMDA price target
• Positive Sentiment: Citizens JMP also boosted its target and reiterated a market outperform rating, adding to the bullish analyst sentiment around OMDA. Citizens JMP raises OMDA price target
• Positive Sentiment: Wells Fargo lifted its target as well, suggesting Wall Street sees more room for Omada Health despite maintaining an equal-weight view. Wells Fargo raises OMDA price target
• Positive Sentiment: Needham reaffirmed its buy rating and set a much higher target, reinforcing confidence in Omada’s growth outlook. Needham reiterates buy rating on OMDA
• Positive Sentiment: Omada reported Q1 EPS of -$0.05, beating expectations for a smaller loss than analysts projected, while revenue came in at $78.05 million. Omada Q1 2026 earnings report
• Positive Sentiment: The company raised FY2026 revenue guidance to $322 million-$330 million, above the Street’s estimate, signaling stronger expected top-line growth. Omada FY2026 guidance update
• Positive Sentiment: Omada announced it will join Lilly Employer Connect as an independent program administrator, expanding access for its GLP-1 care services and potentially broadening future demand. Omada Health Lilly Employer Connect announcement

Analysts Set New Price Targets

OMDA has been the topic of a number of recent research reports. Citizens Jmp upped their price target on Omada Health from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Friday. Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Morgan Stanley dropped their price objective on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, March 6th. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a research note on Friday. Finally, Barclays boosted their price target on shares of Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Omada Health presently has a consensus rating of “Moderate Buy” and an average target price of $22.91.

Insider Activity at Omada Health

In other Omada Health news, CEO Sean P. Duffy sold 4,063 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $14.34, for a total value of $58,263.42. Following the sale, the chief executive officer owned 117,598 shares of the company’s stock, valued at $1,686,355.32. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, President Wei-Li Shao sold 2,829 shares of Omada Health stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $12.71, for a total value of $35,956.59. Following the sale, the president owned 328,850 shares of the company’s stock, valued at approximately $4,179,683.50. This trade represents a 0.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,776 shares of company stock valued at $120,483.

Institutional Investors Weigh In On Omada Health

A number of institutional investors and hedge funds have recently bought and sold shares of OMDA. Perceptive Advisors LLC bought a new stake in Omada Health during the second quarter valued at approximately $44,402,000. Millennium Management LLC raised its position in shares of Omada Health by 1,195.0% during the 4th quarter. Millennium Management LLC now owns 2,272,168 shares of the company’s stock valued at $35,855,000 after buying an additional 2,096,705 shares in the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of Omada Health during the 3rd quarter worth $30,510,000. Jefferies Financial Group Inc. bought a new stake in shares of Omada Health during the 4th quarter worth $16,948,000. Finally, SG Americas Securities LLC purchased a new position in Omada Health in the first quarter worth $10,401,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.